Rate of vision loss in neovascular age-related macular degeneration explored

Autores
Real, Juan Pablo; Granero, Gladys Ester; de Santis, Mariana Olga; Juarez, Claudio P.; Palma, Santiago Daniel; Kelly, Simon P.; Luna, José Domingo
Año de publicación
2015
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Purpose: To explore decline in visual acuity in patients with neovascular age-related macular degeneration (n-AMD) awaiting intravitreal bevacizumab or ranibizumab treatment following initial diagnosis and after disease reactivation. Methods: Retrospective analysis of 74 treatment-naïve patients (84 eyes) in two centers in Córdoba, Argentina. The time between treatment indication and intravitreal injection, and the changes in BCVA produced during this delay were studied in both periods. A linear regression model to search the impact of time on progression visual impairment was conducted. Results: In both periods, a significant reduction in vision occurred awaiting intravitreal injection. The longer the delay, the greater the vision loss (R2 = 0.55 p < 0.01) and the less improvement following treatment (Pearson coefficient −0.26). The result of the model shows that the change in vision as a function of initial delay were best described by a polynomic model with a mean loss of 5 letters in the first 3 weeks, a slowdown in the rate of change of VA, and a dependence of visual acuity at the moment of diagnosis. The loss of visual acuity after reactivation shows the same behavior as at the onset of the disease but independent of visual acuity prior to reactivation. Conclusion: Visual loss awaiting injection intravitreal anti-VEGF is clinically significant and with an asymptotic pattern, with early rapid loss of vision in both the onset of the disease and the reactivation. Initiation of anti-VEGF treatment must be undertaken urgently, as should retreatment of disease activation to reduce visual loss.
Fil: Real, Juan Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; Argentina
Fil: Granero, Gladys Ester. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; Argentina
Fil: de Santis, Mariana Olga. Universidad Nacional de Córdoba. Facultad de Ciencias Económicas. Departamento de Economía y Finanzas; Argentina
Fil: Juarez, Claudio P.. Centro Privado de Ojos Romagosa; Argentina
Fil: Palma, Santiago Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; Argentina
Fil: Kelly, Simon P.. Royal Bolton Hospital; Reino Unido
Fil: Luna, José Domingo. Centro Privado de Ojos Romagosa; Argentina
Materia
AGE-RELATED MACULAR DEGENERATION
BEVACIZUMAB
DISEASE PROGRESSION
HEALTH SYSTEMS
PATIENT SAFETY
RANIBIZUMAB
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/185832
Acceder
id CONICETDig_b29f3194e43babe12d533cd2051bd6d5
oai_identifier_str oai:ri.conicet.gov.ar:11336/185832
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Rate of vision loss in neovascular age-related macular degeneration exploredReal, Juan PabloGranero, Gladys Esterde Santis, Mariana OlgaJuarez, Claudio P.Palma, Santiago DanielKelly, Simon P.Luna, José DomingoAGE-RELATED MACULAR DEGENERATIONBEVACIZUMABDISEASE PROGRESSIONHEALTH SYSTEMSPATIENT SAFETYRANIBIZUMABhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Purpose: To explore decline in visual acuity in patients with neovascular age-related macular degeneration (n-AMD) awaiting intravitreal bevacizumab or ranibizumab treatment following initial diagnosis and after disease reactivation. Methods: Retrospective analysis of 74 treatment-naïve patients (84 eyes) in two centers in Córdoba, Argentina. The time between treatment indication and intravitreal injection, and the changes in BCVA produced during this delay were studied in both periods. A linear regression model to search the impact of time on progression visual impairment was conducted. Results: In both periods, a significant reduction in vision occurred awaiting intravitreal injection. The longer the delay, the greater the vision loss (R2 = 0.55 p < 0.01) and the less improvement following treatment (Pearson coefficient −0.26). The result of the model shows that the change in vision as a function of initial delay were best described by a polynomic model with a mean loss of 5 letters in the first 3 weeks, a slowdown in the rate of change of VA, and a dependence of visual acuity at the moment of diagnosis. The loss of visual acuity after reactivation shows the same behavior as at the onset of the disease but independent of visual acuity prior to reactivation. Conclusion: Visual loss awaiting injection intravitreal anti-VEGF is clinically significant and with an asymptotic pattern, with early rapid loss of vision in both the onset of the disease and the reactivation. Initiation of anti-VEGF treatment must be undertaken urgently, as should retreatment of disease activation to reduce visual loss.Fil: Real, Juan Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; ArgentinaFil: Granero, Gladys Ester. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; ArgentinaFil: de Santis, Mariana Olga. Universidad Nacional de Córdoba. Facultad de Ciencias Económicas. Departamento de Economía y Finanzas; ArgentinaFil: Juarez, Claudio P.. Centro Privado de Ojos Romagosa; ArgentinaFil: Palma, Santiago Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; ArgentinaFil: Kelly, Simon P.. Royal Bolton Hospital; Reino UnidoFil: Luna, José Domingo. Centro Privado de Ojos Romagosa; ArgentinaSpringer2015-11info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/185832Real, Juan Pablo; Granero, Gladys Ester; de Santis, Mariana Olga; Juarez, Claudio P.; Palma, Santiago Daniel; et al.; Rate of vision loss in neovascular age-related macular degeneration explored; Springer; Graefes Archive For Clinical And Experimental Ophthalmology; 253; 11; 11-2015; 1859-18650721-832X1435-702XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://link.springer.com/article/10.1007/s00417-014-2885-yinfo:eu-repo/semantics/altIdentifier/doi/10.1007/s00417-014-2885-yinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:26:04Zoai:ri.conicet.gov.ar:11336/185832instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:26:04.577CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Rate of vision loss in neovascular age-related macular degeneration explored
title Rate of vision loss in neovascular age-related macular degeneration explored
spellingShingle Rate of vision loss in neovascular age-related macular degeneration explored
Real, Juan Pablo
AGE-RELATED MACULAR DEGENERATION
BEVACIZUMAB
DISEASE PROGRESSION
HEALTH SYSTEMS
PATIENT SAFETY
RANIBIZUMAB
title_short Rate of vision loss in neovascular age-related macular degeneration explored
title_full Rate of vision loss in neovascular age-related macular degeneration explored
title_fullStr Rate of vision loss in neovascular age-related macular degeneration explored
title_full_unstemmed Rate of vision loss in neovascular age-related macular degeneration explored
title_sort Rate of vision loss in neovascular age-related macular degeneration explored
dc.creator.none.fl_str_mv Real, Juan Pablo
Granero, Gladys Ester
de Santis, Mariana Olga
Juarez, Claudio P.
Palma, Santiago Daniel
Kelly, Simon P.
Luna, José Domingo
author Real, Juan Pablo
author_facet Real, Juan Pablo
Granero, Gladys Ester
de Santis, Mariana Olga
Juarez, Claudio P.
Palma, Santiago Daniel
Kelly, Simon P.
Luna, José Domingo
author_role author
author2 Granero, Gladys Ester
de Santis, Mariana Olga
Juarez, Claudio P.
Palma, Santiago Daniel
Kelly, Simon P.
Luna, José Domingo
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv AGE-RELATED MACULAR DEGENERATION
BEVACIZUMAB
DISEASE PROGRESSION
HEALTH SYSTEMS
PATIENT SAFETY
RANIBIZUMAB
topic AGE-RELATED MACULAR DEGENERATION
BEVACIZUMAB
DISEASE PROGRESSION
HEALTH SYSTEMS
PATIENT SAFETY
RANIBIZUMAB
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Purpose: To explore decline in visual acuity in patients with neovascular age-related macular degeneration (n-AMD) awaiting intravitreal bevacizumab or ranibizumab treatment following initial diagnosis and after disease reactivation. Methods: Retrospective analysis of 74 treatment-naïve patients (84 eyes) in two centers in Córdoba, Argentina. The time between treatment indication and intravitreal injection, and the changes in BCVA produced during this delay were studied in both periods. A linear regression model to search the impact of time on progression visual impairment was conducted. Results: In both periods, a significant reduction in vision occurred awaiting intravitreal injection. The longer the delay, the greater the vision loss (R2 = 0.55 p < 0.01) and the less improvement following treatment (Pearson coefficient −0.26). The result of the model shows that the change in vision as a function of initial delay were best described by a polynomic model with a mean loss of 5 letters in the first 3 weeks, a slowdown in the rate of change of VA, and a dependence of visual acuity at the moment of diagnosis. The loss of visual acuity after reactivation shows the same behavior as at the onset of the disease but independent of visual acuity prior to reactivation. Conclusion: Visual loss awaiting injection intravitreal anti-VEGF is clinically significant and with an asymptotic pattern, with early rapid loss of vision in both the onset of the disease and the reactivation. Initiation of anti-VEGF treatment must be undertaken urgently, as should retreatment of disease activation to reduce visual loss.
Fil: Real, Juan Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; Argentina
Fil: Granero, Gladys Ester. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; Argentina
Fil: de Santis, Mariana Olga. Universidad Nacional de Córdoba. Facultad de Ciencias Económicas. Departamento de Economía y Finanzas; Argentina
Fil: Juarez, Claudio P.. Centro Privado de Ojos Romagosa; Argentina
Fil: Palma, Santiago Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; Argentina
Fil: Kelly, Simon P.. Royal Bolton Hospital; Reino Unido
Fil: Luna, José Domingo. Centro Privado de Ojos Romagosa; Argentina
description Purpose: To explore decline in visual acuity in patients with neovascular age-related macular degeneration (n-AMD) awaiting intravitreal bevacizumab or ranibizumab treatment following initial diagnosis and after disease reactivation. Methods: Retrospective analysis of 74 treatment-naïve patients (84 eyes) in two centers in Córdoba, Argentina. The time between treatment indication and intravitreal injection, and the changes in BCVA produced during this delay were studied in both periods. A linear regression model to search the impact of time on progression visual impairment was conducted. Results: In both periods, a significant reduction in vision occurred awaiting intravitreal injection. The longer the delay, the greater the vision loss (R2 = 0.55 p < 0.01) and the less improvement following treatment (Pearson coefficient −0.26). The result of the model shows that the change in vision as a function of initial delay were best described by a polynomic model with a mean loss of 5 letters in the first 3 weeks, a slowdown in the rate of change of VA, and a dependence of visual acuity at the moment of diagnosis. The loss of visual acuity after reactivation shows the same behavior as at the onset of the disease but independent of visual acuity prior to reactivation. Conclusion: Visual loss awaiting injection intravitreal anti-VEGF is clinically significant and with an asymptotic pattern, with early rapid loss of vision in both the onset of the disease and the reactivation. Initiation of anti-VEGF treatment must be undertaken urgently, as should retreatment of disease activation to reduce visual loss.
publishDate 2015
dc.date.none.fl_str_mv 2015-11
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/185832
Real, Juan Pablo; Granero, Gladys Ester; de Santis, Mariana Olga; Juarez, Claudio P.; Palma, Santiago Daniel; et al.; Rate of vision loss in neovascular age-related macular degeneration explored; Springer; Graefes Archive For Clinical And Experimental Ophthalmology; 253; 11; 11-2015; 1859-1865
0721-832X
1435-702X
CONICET Digital
CONICET
url http://hdl.handle.net/11336/185832
identifier_str_mv Real, Juan Pablo; Granero, Gladys Ester; de Santis, Mariana Olga; Juarez, Claudio P.; Palma, Santiago Daniel; et al.; Rate of vision loss in neovascular age-related macular degeneration explored; Springer; Graefes Archive For Clinical And Experimental Ophthalmology; 253; 11; 11-2015; 1859-1865
0721-832X
1435-702X
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://link.springer.com/article/10.1007/s00417-014-2885-y
info:eu-repo/semantics/altIdentifier/doi/10.1007/s00417-014-2885-y
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846781816334188544
score 12.982451

Publicaciones similares